Niagen Bioscience Inc. (NAGE)
NASDAQ: NAGEHealth Care Medicinal Chemicals and Botanical Products USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NAGE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $145.72M
- P/E (TTM)
- 15.33
- EPS (TTM)
- $0.12
- Dividend yield
- None
- 52-week range
- 1.79 – 7.11
- Day range
- 1.79 – 1.86
- Volume / Avg
- 1.39M / 522.66K
- Beta
- —
- Shares outstanding
- 79.20M
52-week range
NAGE stock today
On Nov 20, NAGE ended the session at $1.84, shedding $0.03 (1.60%), versus the S&P 500's 3.70% decline. Volume was 2.7x the average at 1.39M shares, a sign of unusually heavy trading. Shares are 74.1% below their 52-week high of $7.11, set on Nov 25, 2025 and 2.8% above the 52-week low of $1.79, near the bottom of the past year's range.
NAGE is down 71.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 73.3%. Niagen Bioscience trades at 15.3x its trailing twelve-month earnings per share of $0.12.
Summary generated from market data by MetaCap's automated system. Methodology
About Niagen Bioscience
Company profileNiagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- CEO
- Mr. Robert N. Fried
- Headquarters
- Los Angeles, CA
- Employees
- 117
- Website
- niagenbioscience.com
Financial highlights
Full financialsIn fiscal 2025, Niagen Bioscience generated $129.4 million in revenue, up 29.9% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $17.4 million (+103.3% year over year), for a net margin of 13.4% versus a median of -23.0% in the prior 5 years. Gross margin was 64.3% (up from 61.8%) and operating margin 12.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $129.42M | $99.60M | $83.57M | $72.05M | $67.45M |
| Growth | +29.95% | +19.18% | +15.99% | +6.82% | +13.82% |
| Net income | $17.38M | $8.55M | $-4.94M | $-16.54M | $-27.13M |
| EPS (diluted) | $0.20 | $0.11 | $-0.07 | $-0.24 | $-0.40 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$10.67+479.89%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.05 vs $-0.01
- Surprise
- +600.00%
NAGE news
All NAGE news- Niagen (NAGE) Q3 2026 Earnings Call TranscriptNasdaqNAGE, BF.A
- Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial ResultsNasdaqNAGE, BRK.A
- Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue EstimatesNasdaqNAGE, PTGX
- Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026Business Wire
Niagen Bioscience peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GLASGlass House Brands Inc. Subordinate Voting Shares | 1.18 | -2.48% | $118.11M | vs NAGE |
| CGCCanopy Growth Corporation | 0.427 | -9.97% | $191.99M | vs NAGE |
| MDWDMediWound Ltd. | 13.59 | +0.37% | $195.56M | vs NAGE |
| ISPRIspire Technology Inc. | 1.23 | -3.15% | $71.05M | vs NAGE |
| FTLFFitLife Brands Inc. | 6.20 | -7.46% | $58.22M | vs NAGE |
| USNAUSANA Health Sciences Inc. | 12.94 | -1.67% | $239.24M | vs NAGE |
| BTMDBiote Corp. Class A | 0.8147 | -3.56% | $26.28M | vs NAGE |
| ACBAurora Cannabis Inc. | 4.16 | -2.35% | $273.50M | vs NAGE |
Indexes, lists and sector
Niagen Bioscience stock FAQ
What is Niagen Bioscience's stock price today?
NAGE last traded at $1.84 as of Nov 20, 4:00 PM EST, down 1.60% on the day. Prices are delayed at least 15 minutes.
Does Niagen Bioscience pay a dividend?
No. Niagen Bioscience does not currently pay a regular cash dividend.
What is NAGE's P/E ratio?
NAGE trades at a trailing P/E ratio of 15.33.
Who is Niagen Bioscience's CEO?
Mr. Robert N. Fried is the chief executive officer of Niagen Bioscience Inc., which has about 117 employees.
Has NAGE ever split its stock?
Yes. The most recent NAGE stock split was a 1-for-3 split on Apr 13, 2016.
What is the NAGE 52-week high?
The 52-week high for NAGE is $7.11 and the 52-week low is $1.79. The stock is currently 74.1% below its high.